The U.S. Food and Drug Administration noted that cannabidiol shouldn’t be a controlled substance, but international treaties require the United States to treat it as one.
“CBD has negligible potential for abuse,” wrote Dr. Brett Giroir, the assistant secretary for health in the U.S. Health and Human Services Department, the FDA’s parent agency.
Giroir noted that CBD doesn’t meet the description of even the least-restrictive class of controlled substances, Schedule 5, but that international drug treaties require the nation to control the cannabis extract.
If those treaties were to change, he added, “the above recommendation … would need to be revised promptly.”
The letter was written to advise the U.S. Drug Enforcement Administration about how to classify CBD. Before then, the DEA considered cannabis extracts to be in the most restrictive class of drugs, Schedule 1.
The letter was dated May 16 but became public Friday, after the DEA announced that FDA-approved cannabis drugs with no more than 0.1% THC could be classified as Schedule 5. Currently, that definition only applies to Epidiolex.
The DEA said that cannabis extracts with more than 0.1% THC will remain on Schedule 1.
Epidiolex is manufactured and sold by London-based GW Pharmaceuticals, which derives the extract from marijuana and trades on the Nasdaq as GWPH.
Subscribe to our Newsletter
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers